These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9987141)

  • 81. Acute polyarthritis after influenza A (H1N1) immunization.
    Tabache F; El Kartouti A; Naitlhou A; Hassikou H; Tarib A; Baaj M; Cherrah Y
    Joint Bone Spine; 2011 May; 78(3):321-2. PubMed ID: 21444232
    [No Abstract]   [Full Text] [Related]  

  • 82. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
    Fox CB; Haensler J
    Expert Rev Vaccines; 2013 Jul; 12(7):747-58. PubMed ID: 23885820
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.
    Mannino S; Villa M; Apolone G; Weiss NS; Groth N; Aquino I; Boldori L; Caramaschi F; Gattinoni A; Malchiodi G; Rothman KJ
    Am J Epidemiol; 2012 Sep; 176(6):527-33. PubMed ID: 22940713
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly.
    Muszkat M; Friedman G; Schein MH; Naveh P; Greenbaum E; Schlesinger M; Zakay-Rones Z; Yehuda AB
    Vaccine; 2000 Feb; 18(16):1696-9. PubMed ID: 10689151
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Preservative-free influenza vaccine.
    Banzhoff A; Schwenke C; Febbraro S
    Immunol Lett; 2000 Feb; 71(2):91-6. PubMed ID: 10714435
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period.
    Keitel WA; Cate TR; Couch RB; Huggins LL; Hess KR
    Vaccine; 1997 Jul; 15(10):1114-22. PubMed ID: 9269055
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Chimeric hemagglutinin supra-seasonal universal influenza vaccine candidates administered sequentially by the intramuscular route are locally and systemically well-tolerated in rabbits.
    Destexhe É; Grosdidier É; Bouhraoua A; Thirion-Delalande C; Bouzya B; Rouxel RN; Mallett CP; Baumeister J
    Regul Toxicol Pharmacol; 2020 Jun; 113():104625. PubMed ID: 32119974
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design.
    Sasaki E; Hamaguchi I; Mizukami T
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1051-1061. PubMed ID: 32772723
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults.
    Tsai TF
    Infect Chemother; 2013 Jun; 45(2):159-74. PubMed ID: 24265964
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Characteristics of the clinical and immunologic safety of inactivated influenza vaccines in children undergoing multiple immunizations].
    Vasil'eva RI; Merkur'eva LA; Iatsenko VG; Vasil'eva AM; Shvager MM
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):65-9. PubMed ID: 2975452
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of dose on antibody response to subunit influenza vaccine.
    Feery BJ; Hampson AW; Forsyth JR; Evered MG
    Med J Aust; 1977 Sep; 2(10):324-7. PubMed ID: 927252
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling.
    Momose H; Mizukami T; Kuramitsu M; Takizawa K; Masumi A; Araki K; Furuhata K; Yamaguchi K; Hamaguchi I
    PLoS One; 2015; 10(4):e0124392. PubMed ID: 25909814
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Adjuvanted inactivated influenza Vaccine Quadrivalent for Older People.
    Barranco D; Chahine EB
    Sr Care Pharm; 2020 Sep; 35(9):398-402. PubMed ID: 32807264
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years.
    Yoo BW; Kim CO; Izu A; Arora AK; Heijnen E
    Infect Chemother; 2018 Dec; 50(4):301-310. PubMed ID: 30600653
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects.
    Provinciali M; Di Stefano G; Colombo M; Della Croce F; Gandolfi MC; Daghetta L; Anichini M; Della Bitta R; Fabris N
    Mech Ageing Dev; 1994 Dec; 77(2):75-82. PubMed ID: 7745993
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs).
    Glück R
    Vaccine; 1999 Mar; 17(13-14):1782-7. PubMed ID: 10194840
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [The characteristics of the autoimmune reactions in donors immunized with influenza vaccine and staphylococcal anatoxin].
    Krutitskaia LI; Zhebrun AB
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (2):44-7. PubMed ID: 8701655
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Antibodies to squalene in recipients of anthrax vaccine.
    Asa PB; Wilson RB; Garry RF
    Exp Mol Pathol; 2002 Aug; 73(1):19-27. PubMed ID: 12127050
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antibody induction by influenza vaccines in the elderly: a review of the literature.
    Beyer WE; Palache AM; Baljet M; Masurel N
    Vaccine; 1989 Oct; 7(5):385-94. PubMed ID: 2683459
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies.
    Beyer WE; Palache AM; Kerstens R; Masurel N
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):65-70. PubMed ID: 8641306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.